SUBSCRIBE
SUBSCRIBE

Reata Pharmaceuticals, Inc.

NEWS
Reata Pharmaceuticals was acquired by Biogen Inc. in September 2023.
Business
BioSpace Movers and Shakers for Oct. 15
Who mixed things up in the biotech world this past week? Pfizer announces its leadership team, Rheos gets a new COO, and board of directors updates from multiple biopharma companies.
October 15, 2018
 · 
5 min read
 · 
Alex Keown
Drug Development
Reata Announces Positive Phase 2 Data for Bardoxolone Methyl in IgA Nephropathy and Type 1 Diabetic Chronic Kidney Disease
Statistically Significant Improvement in Kidney Function Observed in Both Diseases After 12 Weeks of Treatment
September 27, 2018
 · 
6 min read
Drug Development
Reata Pharmaceuticals Updates Data Release Dates for Ongoing Phase II Trials
Reata Pharmaceuticals has updated the timing of coming data announcements for two ongoing mid-stage trials for rare renal diseases.
February 28, 2018
 · 
2 min read
 · 
Alex Keown
Load More
JOBS
IN THE PRESS
Deals
Reata Pharmaceuticals Stock Trading Halted Today; FDA Advisory Committee to Discuss Bardoxolone for the Treatment of Patients With Chronic Kidney Disease Caused by Alport Syndrome
December 8, 2021
 · 
3 min read
Lone Star Bio
Reata Pharmaceuticals Receives Fast Track Designation From the FDA for Omaveloxolone for the Treatment of Friedreich’s Ataxia
November 18, 2021
 · 
5 min read
Business
Reata Pharmaceuticals, Inc. Announces Third Quarter 2021 Financial Results and Provides an Update on Clinical Development Programs
November 8, 2021
 · 
15 min read
Business
Reata Pharmaceuticals, Inc. to Report Third Quarter 2021 Financial Results and to Provide an Update on Development Programs on November 8, 2021
November 1, 2021
 · 
1 min read
Lone Star Bio
Reata Pharmaceuticals Submits Marketing Authorization Application to the European Medicines Agency for Bardoxolone Methyl in Chronic Kidney Disease Caused by Alport Syndrome
October 28, 2021
 · 
6 min read
Policy
Reata Pharmaceuticals Plans NDA Submission for Omaveloxolone in First Quarter of 2022 Following Completion of Pre-NDA Meeting with FDA
September 30, 2021
 · 
6 min read
Business
Reata Pharmaceuticals, Inc. Announces Second Quarter 2021 Financial Results and Provides an Update on Clinical Development Programs
August 9, 2021
 · 
18 min read
Business
Reata Pharmaceuticals, Inc. to Report Second Quarter 2021 Financial Results and Provide an Update on Development Programs on August 9, 2021
August 2, 2021
 · 
2 min read
Lone Star Bio
Reata Pharmaceuticals Announces Participation in The Goldman Sachs 42nd Annual Global Healthcare Conference
June 7, 2021
 · 
2 min read
Lone Star Bio
Reata Announces that The FDA Has Asked The Company to Request a Pre-NDA Meeting for Omaveloxolone for the Treatment of Friedreich’s Ataxia
May 19, 2021
 · 
5 min read
Load More